NCT02870309View on ClinicalTrials.gov

Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 29, 2016

Primary Completion Date

March 15, 2017

Study Completion Date

March 15, 2017

Conditions
Alpha1-Antitrypsin Deficiency
Interventions
BIOLOGICAL

Alpha-1 MP

Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as α1-antitrypsin

Trial Locations (2)

060-8648

Hokkaido University Hospital, Sapporo

113-8431

Juntendo University Hospital, Tokyo

Sponsors
All Listed Sponsors
collaborator

Grifols Japan K.K.

OTHER

lead

Grifols Therapeutics LLC

INDUSTRY

NCT02870309 - Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency | Biotech Hunter | Biotech Hunter